Premium peptide catalog built for advanced laboratory workflows.
IGF-1
Mechanism of action IGF-1 LR3 is a synthetic analog of native IGF-1, modified by glutamine→arginine substitution at position 3 and N-terminal extension of 13 amino acids. These modifications reduce binding to IGF-binding proteins (IGFBP) by approximately 70-80%, increasing bioactive fraction in circulation. The peptide activates the IGF-1R receptor (tyrosine kinase), activating PI3K/Akt/mTOR pathways (protein synthesis via p70S6K and 4E-BP1 phosphorylation) and PI3K/Akt/GSK3-β (protein degradation suppression via FOXO1). Half-life is extended (20-30 h vs 12-15 h for native IGF-1) with approximately 3-fold higher biological potency. Research applications • Muscle hypertrophy and hyperplasia: satellite cell activation, myonuclear accretion • Protein synthesis and mTOR pathway regulation • Muscle atrophy: modulation of MAFbx/atrogin-1 and MuRF1 • Myotube growth in vitro Biological properties studied • IGF-1R activation and PI3K/Akt/mTOR and GSK3-β pathways • Stimulation of satellite cell proliferation • Increased muscle fibre cross-sectional area • Extended half-life and reduced IGFBP binding • Purity: ≥99% (HPLC) • Presentation: Lyophilized powder • Storage: 2-8°C • Recommended diluent: 0.6% acetic acid (AA) or bacteriostatic water per protocol Research use only.
145,00 €
